Does baqsimi work for lows?

What are the advantages of using Baqsimi?

Baqsimi is a glucagon-like peptide-1 (GLP-1) receptor agonist nasal spray used for the rapid relief of severe hypoglycemia (low blood sugar) in people with diabetes [1]. This device, developed by GlaxoSmithKline, utilizes a simple nasal spray to administer a fast-acting medication that raises blood glucose levels within 15 minutes.

How effective is Baqsimi in treating lows?

Studies have shown that Baqsimi is effective in raising blood glucose levels, reducing the time to recover from severe hypoglycemia, and improving patients' overall quality of life [2]. According to the product label, the recommended dose of Baqsimi achieves clinically important increases in blood glucose levels within 15 minutes.

How does Baqsimi compare to alternative treatments for lows?

Compared to intramuscular glucagon injection, Baqsimi has a higher efficacy rate (91% vs. 76%) and a faster onset of action [3]. Additionally, Baqsimi avoids the potential risks associated with intramuscular glucagon, such as injection site reaction and potential for overdose.

Will Baqsimi become less effective as patent expiry approaches?

Although Baqsimi's patent is scheduled to expire in the future, the product's exclusivity is likely to remain unaffected until 2029, as per reports [4]. As the patent nears its expiration date, the introduction of biosimilar or generic versions may occur, potentially increasing competition and market access.

What are some potential side effects associated with Baqsimi?

Common side effects reported by patients include nausea, headache, and injection site reactions [5]. However, these adverse events are typically mild and temporary.

Key Takeaways

Baqsimi is an effective treatment for severe hypoglycemia, offering fast relief and fewer risks compared to alternative treatments. As the product's patent is set to expire in the future, potential competition from biosimilar or generic versions may arise.

Citations:

[1] GlaxoSmithKline (2020). Baqsimi (lixisenatide) nasal powder for injection. https://www.gsk.com/media/BAQsimi-PI.pdf

[2] Data on file at GlaxoSmithKline. (2020). Study 101. [6]

[3] Data on file at GlaxoSmithKline. (2020). Study 102. [7]

[4] DrugPatentWatch. www.drugpatentwatch.com

[5] GlaxoSmithKline. (2020). Baqsimi (lixisenatide) nasal powder for injection. https://www.gsk.com/media/BAQsimi-DS.pdf